Absci Corporation (NASDAQ: ABSI) announced that the first participants have been dosed in its Phase 1/2a clinical trial evaluating ABS-201 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE